CONSORT Statement 2010: recommendations for reporting randomised trials

Doug Altman

The EQUATOR Network

Centre for Statistics in Medicine, Oxford, UK
“The whole of medicine depends on the transparent reporting of clinical trials”

Drummond Rennie, *JAMA* 2001
“This leads one to consider if it is possible, in planning a trial, in reporting the results, or in assessing the published reports of trials, to apply criteria which must be satisfied if the analysis is to be entirely acceptable.

“A basic principle can be set up that ... it is at least as important to describe the techniques employed and the conditions in which the experiment was conducted, as to give the detailed statistical analysis of results.”

“If cases are allotted to a control group or to a treatment group ... what method of random selection is used?”

“... editors could greatly improve the reporting of clinical trials by providing authors with a list of items that they expected to be strictly reported.”

[DerSimonian R et al, *NEJM* 1982]
Special Communication

Improving the Quality of Reporting of Randomized Controlled Trials

The CONSORT Statement

Colin Begg, PhD; Mildred Cho, PhD; Susan Eastwood, ELS(D); Richard Horton, MB; David Moher, MSc; Ingram Olkin, PhD; Roy Pitkin, MD; Drummond Rennie, MD; Kenneth F. Schulz, PhD; David Simel, MD; Donna F. Stroup, PhD

JAMA, August 28, 1996
<table>
<thead>
<tr>
<th>Heading</th>
<th>Subheading</th>
<th>Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td></td>
<td>Identify the study as a randomized trial.</td>
</tr>
<tr>
<td>Abstract</td>
<td></td>
<td>Use a structured format.</td>
</tr>
<tr>
<td>Introduction</td>
<td></td>
<td>State prospectively defined hypothesis, clinical objectives, and planned subgroup or covariate analyses.</td>
</tr>
<tr>
<td>Methods</td>
<td>Protocol</td>
<td>Describe Planned study population, together with inclusion/exclusion criteria. Planned interventions and their timing. Primary and secondary outcome measure(s) and the minimum important difference(s), and indicate how the target sample size was projected. Rationale and methods for statistical analyses, detailing main comparative analyses and whether they were completed on an intention-to-treat basis. Prospectively defined stopping rules (if warranted)</td>
</tr>
<tr>
<td>Assignment</td>
<td></td>
<td>Describe Unit of randomization (e.g., individual, cluster, geographic). Method used to generate the allocation schedule. Method of allocation concealment and timing of assignment. Method to separate the generator from the executor of assignment.</td>
</tr>
<tr>
<td>Masking (Blinding)</td>
<td></td>
<td>Describe mechanism (e.g., capsules, tablets); similarity of treatment characteristics (e.g., appearance, taste); allocation schedule control (location of code during trial and when broken); and evidence for successful blinding among participants, person doing intervention, outcome assessors, and data analysts.</td>
</tr>
<tr>
<td>Results</td>
<td>Participant Flow and Follow-up</td>
<td>Provide a trial profile (Figure) summarizing participant flow, numbers and timing of randomization assignment, interventions, and measurements for each randomized group.</td>
</tr>
<tr>
<td>Analysis</td>
<td></td>
<td>State estimated effect of intervention on primary and secondary outcome measures, including a point estimate and measure of precision (confidence interval). State results in absolute numbers when feasible (e.g., 10/20, not 50%). Present summary data and appropriate descriptive and inferential statistics in sufficient detail to permit alternative analyses and replication. Describe prognostic variables by treatment group and any attempt to adjust for them. Describe protocol deviations from the study as planned, together with the reasons.</td>
</tr>
<tr>
<td>Comment</td>
<td></td>
<td>State specific interpretation of study findings, including sources of bias and imprecision (internal validity) and discussion of external validity, including appropriate quantitative measures when possible. State general interpretation of the data in light of the totality of the available evidence.</td>
</tr>
</tbody>
</table>
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

David Moher, Kenneth F Schulz, Douglas G Altman, for the CONSORT Group*

2001 Revision of CONSORT

- **Major update published in 2001**

- **Checklist** – major revision
  - **Also small changes to flow diagram**

- **Short paper** (“The CONSORT Statement”)
  - published in 3 journals

- **Explanatory paper** (E&E)
  - Detailed explanations and examples
# CONSORT Statement

<table>
<thead>
<tr>
<th>Title and abstract</th>
<th>Item number</th>
<th>Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>How participants were allocated to interventions (eg, “random allocation”, “randomised”, or “randomly assigned”).</td>
</tr>
</tbody>
</table>

## Introduction

| Background | 2 | Scientific background and explanation of rationale.                                                                                                                                                  |

## Methods

<table>
<thead>
<tr>
<th>Participants</th>
<th>3</th>
<th>Eligibility criteria for participants and the settings and locations where the data were collected.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interventions</td>
<td>4</td>
<td>Precise details of the interventions intended for each group and how and when they were actually administered.</td>
</tr>
<tr>
<td>Objectives</td>
<td>5</td>
<td>Specific objectives and hypotheses.</td>
</tr>
<tr>
<td>Outcomes</td>
<td>6</td>
<td>Clearly defined primary and secondary outcome measures and, when applicable, any methods used to enhance the quality of measurements (eg, multiple observations, training of assessors, &amp;c).</td>
</tr>
</tbody>
</table>

## Sample size

| Randomisation  | 7 | How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules.                                                                                     |

## Results

<table>
<thead>
<tr>
<th>Participant flow</th>
<th>13</th>
<th>Flow of participants through each stage (a diagram is strongly recommended). Specifically, for each group, report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analysed for the primary outcome. Describe protocol deviations from study as planned, together with reasons.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recruitment</td>
<td>14</td>
<td>Dates defining the periods of recruitment and follow-up.</td>
</tr>
<tr>
<td>Baseline data</td>
<td>15</td>
<td>Baseline demographic and clinical characteristics of each group.</td>
</tr>
<tr>
<td>Numbers analysed</td>
<td>16</td>
<td>Number of participants (denominator) in each group included in each analysis and whether the analysis was by “intention to treat”. State the results in absolute numbers when feasible (eg, 10/20, not 50%).</td>
</tr>
</tbody>
</table>

## Discussion

<table>
<thead>
<tr>
<th>Interpretation</th>
<th>20</th>
<th>Interpretation of the results, taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generalisability</td>
<td>21</td>
<td>Generalisability (external validity) of the trial findings.</td>
</tr>
<tr>
<td>Overall evidence</td>
<td>22</td>
<td>General interpretation of the results in the context of current evidence.</td>
</tr>
</tbody>
</table>

## Checklist of items to include when reporting a randomised trial

- Title and abstract
- Introduction
- Methods
- Sample size
- Results
- Discussion
- Checklist of items to include when reporting a randomised trial
CONSORT STATEMENT

Flow diagram of the progress through the phases of a randomised trial
Rationale for checklist items

- Necessary to evaluate the study
- Evidence-based, whenever possible
- Minimum set of essential items
The “explanation and elaboration” manuscript

- To enhance the use and dissemination of CONSORT
- For each checklist item: a detailed explanation, examples of good reporting, with relevant empirical evidence

The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration

Douglas G. Altman, DSc; Kenneth F. Schulz, PhD; David Moher, MSc; Matthias Egger, MD; Frank Davidoff, MD; Diana Elbourne, PhD; Peter C. Gøtzsche, MD; and Thomas Lang, MA, for the CONSORT Group
2010 Revision of CONSORT

- Meeting in January 2007
- Revised checklist
- Short paper (published in 9 journals)
- Revised (and expanded) explanatory paper (E&E)

Schulz et al. Trials 2010, 11:32
http://www.trialsjournal.com/content/11/1/32

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

Kenneth F Schulz¹*, Douglas G Altman², David Moher³, the CONSORT Group
CONSORT checklist 2010 (25 items)

**TITLE & ABSTRACT**

**INTRODUCTION**
- Background
- Objectives

**METHODS**
- Trial design
- Participants
- Interventions
- Outcomes
- Sample size
- Randomization
  - Sequence generation
  - Allocation concealment
  - Implementation
- Blinding (Masking)
- Statistical methods

**RESULTS**
- Participant flow
- Recruitment
- Baseline data
- Numbers analyzed
- Outcomes and Estimation
- Ancillary analyses
- Harms

**DISCUSSION**
- Limitations
- Generalisability
- Interpretation

**OTHER INFORMATION**
- Registration
- Protocol
- Funding
Major changes in 2010

- **Added 3 new items**
  - Registration, Protocol, Funding

- **Added several sub-items, e.g.**
  - Any important changes to methods after trial commencement, with a discussion of reasons
  - Why the trial ended or was stopped

- **Made some items more specific**
  - e.g. allocation concealment mechanism, blinding

- **We simplified and clarified the wording throughout**

- All changes are documented in the paper
Box 2. Noteworthy Specific Changes in CONSORT 2010 Statement

- **Item 1b (title and abstract)**—We added a sub-item on providing a structured summary of trial design, methods, results, and conclusions and referenced the CONSORT for abstracts article [21].
- **Item 2b (introduction)**—We added a new sub-item (formerly item 5 in CONSORT 2001) on “Specific objectives or hypotheses”.
- **Item 3a (trial design)**—We added a new item including this sub-item to clarify the basic trial design (such as parallel group, crossover, cluster) and the allocation ratio.
- **Item 3b (trial design)**—We added a new sub-item that addresses any important changes to methods after trial commencement, with a discussion of reasons.
- **Item 4 (participants)**—Formerly item 3 in CONSORT 2001.
- **Item 5 (interventions)**—Formerly item 4 in CONSORT 2001. We encouraged greater specificity by stating that descriptions of interventions should include “sufficient details to allow replication” [3].
- **Item 6 (outcomes)**—We added a sub-item on identifying any changes to the primary and secondary outcome (endpoint) measures after the trial started. This followed from empirical evidence that authors frequently provide analyses of outcomes in their published papers that were not the prespecified primary and secondary outcomes in their protocols, while ignoring their prespecified outcomes (that is, selective outcome reporting). [4,22] We eliminated text on any methods used to enhance the quality of measurements.
- **Item 9 (allocation concealment mechanism)**—We reworded this to include mechanism in both the report topic and the descriptor to reinforce that authors should report the actual steps taken to ensure allocation concealment rather than simply report imprecise, perhaps banal, assurances of concealment.
- **Item 11 (blinding)**—We added the specification of how blinding was done and, if relevant, a description of the similarity of interventions and procedures. We also eliminated text on “how the success of blinding (masking) was assessed” because of a lack of empirical evidence supporting the practice as well as theoretical concerns about the validity of any such assessment [23,24].
- **Item 12a (statistical methods)**—We added that statistical methods should also be provided for analysis of secondary outcomes.
- **Sub-Item 14b (recruitment)**—Based on empirical research, we added a sub-item on “Why the trial ended or was stopped” [25].
- **Item 15 (baseline data)**—We specified “A table” to clarify that baseline and clinical characteristics of each group are most clearly expressed in a table.
- **Item 16 (numbers analysed)**—We replaced mention of “intention to treat” analysis, a widely misused term, by a more explicit request for information about retaining participants in their original assigned groups [26].
- **Sub-Item 17b (outcomes and estimation)**—For appropriate clinical interpretability, prevailing experience suggested the addition of “For binary outcomes, presentation of both relative and absolute effect sizes is recommended” [27].
- **Item 19 (harms)**—We included a reference to the CONSORT paper on harms [28].
- **Item 20 (limitations)**—We changed the topic from “Interpretation” and supplanted the prior text with a sentence focusing on the reporting of sources of potential bias and imprecision.
- **Item 22 (interpretation)**—We changed the topic from “Overall evidence.” Indeed, we understand that authors should be allowed leeway for interpretation under this nebulous heading. However, the CONSORT Group expressed concerns that conclusions in papers frequently misrepresented the actual analytical results and that harms were ignored or marginalised. Therefore, we changed the checklist item to include the concepts of results matching interpretations and of benefits being balanced with harms.
- **Item 23 (registration)**—We added a new item on trial registration. Empirical evidence supports the need for trial registration, and recent requirements by journal editors have fostered compliance [29].
- **Item 24 (protocol)**—We added a new item on availability of the trial protocol. Empirical evidence suggests that authors often ignore, in the conduct and reporting of their trial, what they stated in the protocol. [4,22] Hence, availability of the protocol can instigate adherence to the protocol before publication and facilitate assessment of adherence after publication.
- **Item 25 (funding)**—We added a new item on funding. Empirical evidence points toward funding source sometimes being associated with estimated treatment effects [30].
Blinding in CONSORT 2010

- We added the specification of how blinding was done and, if relevant, a description of the similarity of interventions and procedures.
- We eliminated text on “how the success of blinding (masking) was assessed”
  - lack of empirical evidence supporting the practice
  - theoretical concerns about the validity of such assessment
Evolution of the CONSORT Statement

Outcomes

- **CONSORT 1996**
  - “Primary and secondary outcome measure(s) ...”

- **CONSORT 2001**
  - “Clearly defined primary and secondary outcome measures ...”

- **CONSORT 2010**
  - “Completely defined prespecified primary and secondary outcome measures, including how and when they were assessed”
Evolution of the CONSORT Statement

Interventions

- **CONSORT 1996**
  - “Planned interventions and their timing”

- **CONSORT 2001**
  - “Precise details of the interventions intended for each group and how and when they were actually administered”

- **CONSORT 2010**
  - “The interventions for each group with sufficient details to allow replication, including how and when they were actually administered”
What do we need to know about treatment allocation?

- Was the allocation sequence generated in an appropriately unpredictable way, e.g. by randomization [“Sequence generation”]
  - How was the sequence determined?

- Was the act of allocating a treatment to a patient done without any knowledge of what treatment they will get? [“Allocation concealment”]
  - What was the mechanism of allocation?
Description of randomization in RCTs

So important that CONSORT checklist has 3-4 items:

*Item 8a.* Method used to generate the random allocation sequence

*Item 8b.* Type of randomisation; details of any restriction (such as blocking and block size)

*Item 9.* Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

*Item 10.* Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions
Good (clear) reporting

Sequence generation:

- “Independent pharmacists dispensed either active or placebo inhalers according to a computer generated randomization list.” [Bolliger et al, BMJ 2000]
- ... The randomization code was developed using a computer random number generator to select random permuted blocks. The block lengths were 4, 8, and 10 varied randomly ...” [Coutinho et al, Obstet Gynecol 2008]
Clear reporting but poor methodology

“Randomization was alternated every 10 patients, such that the first 10 patients were assigned to early atropine and the next 10 to the regular protocol, etc. To avoid possible bias, the last 10 were also assigned to early atropine.”

Impact of CONSORT

- **CONSORT has wide support from journals**
  - >600 journals
  - Editorial groups:
    - Council of Science Editors
    - World Association of Medical Editors
    - International Committee of Medical Journal Editors
  - Peer review granting agencies
    - Canadian Institutes of Health Research

- **Most reporting guidelines have had limited impact**
  - Passive dissemination through publication only
  - Compliance not required by journals
  - Potential impact of CONSORT not being realised
EDITORIAL

Adoption of CONSORT Statements for Randomized Control Trials Published in the Journal of Pediatric Nursing

We are pleased to announce our editorial decision to adopt the Consolidated Standards of Reporting Trials (CONSORT) Statement guidelines for the publication of randomized control trials (RCTs) in the Journal of Pediatric Nursing (JPN; CONSORT, 2010a). The CONSORT Statement number of publication guidelines for various types of research studies have been developed. (For additional information, the reader is referred to the EQUATOR Network website listed below, which contains the complication of health research reporting guidelines; Equator Network: Enhancing the quality and transparency of health research, n.d.) The adoption of reporting guidelines by interdisciplinary journals in health care will assist authors in the composition of their submissions and reviewers to assess the merits of manuscripts. Ultimately, the contributions to the body of knowledge in the specialty

Betz, 2011
Welcome to the CONSORT Statement Website

CONSORT, which stands for Consolidated Standards of Reporting Trials, encompasses various initiatives developed by the CONSORT Group to alleviate the problems arising from inadequate reporting of randomized controlled trials (RCTs).

The main product of CONSORT is the CONSORT Statement, which is an evidence-based, minimum set of recommendations for reporting RCTs. It offers a standard way for authors to prepare reports of trial findings, facilitating their complete and transparent reporting, and aiding their critical appraisal and interpretation.

The CONSORT Statement comprises a 22-item checklist and a flow diagram, along with some brief descriptive text. The checklist items focus on reporting how the trial was designed, analyzed, and interpreted; the flow diagram displays the progress of all participants through the trial. The Statement has been translated into several languages.

Considered an evolving document, the CONSORT Statement is subject to periodic changes as new evidence emerges. This website contains the current definitive version of the CONSORT Statement and up-to-date information on extensions.

The CONSORT "Explanation and Elaboration" document explains and illustrates the principles underlying the CONSORT Statement. We strongly recommend that it is used in conjunction with the CONSORT Statement.

In addition, Extensions of the CONSORT Statement have been developed to give additional guidance for RCTs with specific designs, data, and interventions.

The CONSORT Statement is endorsed by prominent general medical journals, many specialty medical journals, and leading editorial organizations.

CONSORT is part of a broader effort, to improve the reporting of different types of health research, and
www.consort-statement.org
Closing thoughts

- Findings of all randomised trials should be published
- Trial reports should be complete and transparent
- Many trials reports omit crucial information, weakening their clinical value
- Peer reviewers and editors are failing to ensure that reports of trials are usable by readers
- Adherence to the CONSORT checklist and flow diagram would maximise the value of trial reports
- Journals should institute systems to ensure compliance with CONSORT
Evolution of the CONSORT Statement

Blinding

- **CONSORT 1996**
  - “Describe mechanism (e.g., capsules, tablets); similarity of treatment characteristics (e.g., appearance, taste); allocation schedule control (location of code during trial and when broken); and evidence for successful blinding among participants, person doing intervention, outcome assessors, and data analysts.”

- **CONSORT 2001**
  - “Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment. If done, how the success of blinding was evaluated.”

- **CONSORT 2010**
  - “If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
  - If relevant, description of the similarity of interventions”